阿达木单抗联合甲氨蝶呤治疗类风湿关节炎的疗效与甲氨蝶呤相关毒性
基于CONCERTO和MUSICA两项试验,评估阿达木单抗联合不同剂量甲氨蝶呤治疗类风湿关节炎的疗效与甲氨蝶呤相关毒性。结果显示ACR50应答率随时间增加,而甲氨蝶呤相关不良事件发生率保持稳定,最高约30%患者出现不良事件且多为轻度,仅0.5%-1.3%患者因不良事件停用甲氨蝶呤。
要点
- 联合治疗中ACR50应答率随时间上升,CONCERTO第26周为54%-68%,MUSICA第24周为32.3%-37.5%。
- 甲氨蝶呤相关不良事件发生率稳定,CONCERTO第26周2.4%-17.8%,MUSICA第24周6.5%。
- 甲氨蝶呤相关不良事件最高约30%患者报告,多为轻度,仅0.5%-1.3%患者因此停药。
核心结论
- 在开始阿达木单抗联合甲氨蝶呤的类风湿关节炎患者中,两项试验均观察到疗效随时间增加,而甲氨蝶呤相关不良事件发生率保持稳定。
- 甲氨蝶呤相关不良事件在高达30%的患者中观察到的,且大多数为轻度,仅0.5%-1.3%的患者停用甲氨蝶呤。
研究设计与样本
- 数据来自CONCERTO试验:早期类风湿关节炎患者起始阿达木单抗联合甲氨蝶呤2.5、5、10或20 mg/周,治疗26周。
- 数据来自MUSICA试验:对甲氨蝶呤应答不足的患者起始阿达木单抗联合甲氨蝶呤7.5或20 mg/周,治疗24周。
- 疗效采用美国风湿病学会50(ACR50)评估,甲氨蝶呤相关毒性信息通过每次访视时收集18项预设的甲氨蝶呤相关不良事件。
主要发现
- CONCERTO中ACR50应答率随时间增加,第26周范围为54%至68%,不良事件发生率保持稳定,第26周范围为2.4%至17.8%。
- CONCERTO的395例患者中113例(28.6%)报告345例甲氨蝶呤相关不良事件,包括1例严重不良事件(过度疲劳和/或不适),10例不良事件(涉及2例患者)导致研究终止。
- MUSICA中ACR50应答率随时间增加,第24周分别为32.3%和37.5%,甲氨蝶呤相关不良事件发生率保持稳定,第24周为6.5%。
- MUSICA的309例患者中71例(23%)报告185例甲氨蝶呤相关不良事件,包括5例严重不良事件(4例感染和1例发热/寒战),6例不良事件(涉及4例患者)导致研究终止。
关键数值与推荐
- CONCERTO第26周ACR50应答率范围54%至68%,甲氨蝶呤相关不良事件发生率范围2.4%至17.8%。
- MUSICA第24周ACR50应答率分别为32.3%和37.5%,甲氨蝶呤相关不良事件发生率为6.5%。
- CONCERTO中甲氨蝶呤相关不良事件报告率28.6%(113/395),MUSICA中为23%(71/309)。
- 甲氨蝶呤停药率范围为0.5%-1.3%。
临床怎么用
- 对于开始阿达木单抗联合甲氨蝶呤的类风湿关节炎患者,应预期疗效随治疗时间增加。
- 甲氨蝶呤相关不良事件最高约30%患者报告但多为轻度,因不良事件停用甲氨蝶呤的比例仅0.5%-1.3%。
- 治疗期间需按预设的甲氨蝶呤相关不良事件清单进行监测,多数不良事件无需停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of rheumatoid arthritis (RA) with a combination of methotrexate (MTX)+adalimumab (ADA) is more effective than ADA monotherapy. We assessed the toxicity of different doses of MTX and treatment efficacy of ADA+MTX in two trials. METHODS: Data originated from CONCERTO, in patients with early RA initiating ADA+ 2.5, 5, 10 or 20 mg/week MTX for 26 weeks; and MUSICA, in patients with an inadequate response to MTX initiating ADA+ 7.5 or 20 mg/week MTX for 24 weeks. Efficacy was assessed by the American College of Rheumatology 50 (ACR50). Patient-reported MTX-related toxicity information was collected at each visit on 18 prespecified MTX-related adverse events (AE) in the MTX label. RESULTS: In CONCERTO, ACR50 rates increased over time, ranging from 54% to 68% at week 26, while AE rates remained steady, ranging from 2.4% to 17.8% at week 26. Of 395 patients, 113 (28.6%) reported 345 MTX-related AEs, including one serious AE (SAE, excessive fatigue and/or malaise); 10 AEs (in two patients) led to study discontinuation. In MUSICA, ACR50 rates increased over time, and were 32.3% and 37.5% at week 24, while MTX-related AE rates remained steady and were 6.5% at week 24. Of 309 patients, 71 (23%) reported 185 MTX-related AEs, including 5 SAEs (four infections and one fever/chills); six AEs (in four patients) led to study discontinuation. CONCLUSION: In patients with RA initiating ADA+MTX combination, treatment efficacy was achieved and increased throughout both trials, while rates of MTX-related AEs remained steady. MTX-related AEs were observed in up to 30% of patients and most were mild. MTX was discontinued by 0.5%-1.3% of patients. TRIAL REGISTRATION NUMBER: MUSICA (NCT01185288), CONCERTO (NCT01185301), Post results.
引用
- Burmester GR, Kaeley GS, Kavanaugh AF, et al. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017. PMID: 28955494. doi:10.1136/rmdopen-2017-000465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。